|
INmune Bio, Inc. Announces Key Breast Cancer Treatment Resistance Data to be Presented at the 2021 San Antonio Breast Cancer Symposium
|
09 Dec, 2021 |
|
INmune Bio, Inc. Announces Two Presentations at the 2021 British Society of Immunology Congress and Provides 119-day data on First patient in MDS trial.
|
01 Dec, 2021 |
|
INmune Bio, Inc. Announces Third Quarter 2021 Results and Provides Business Update
|
03 Nov, 2021 |
|
INmune Bio, Inc. Announces Multiple Oral and Poster Presentations at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting
|
27 Oct, 2021 |
|
INmune Bio, Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, November 3
|
25 Oct, 2021 |
|
INmune Bio, Inc. to Participate in the B. Riley Fall 2021 Best Ideas in Oncology Series
|
27 Sep, 2021 |
|
INmune Bio, Inc. Announces Participation at Upcoming Investor Conferences
|
20 Sep, 2021 |
|
Alzheimer’s Patients Treated with INmune Bio’s XPro™ Show Reduction in CSF Phospho-Tau and Evidence of Remyelination
|
01 Sep, 2021 |
|
INmune Bio, Inc. Announces Biomarker Data Demonstrating that the First Patient Treated with its NK Cell Priming “Pseudokine”, INKmune™, Successfully Produced Memory-Like NK Cells
|
25 Aug, 2021 |
|
INmune Bio, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference
|
10 Aug, 2021 |
|
INmune Bio, Inc. to Present at the BTIG Virtual Biotechnology Conference
|
05 Aug, 2021 |
|
INmune Bio, Inc. Announces Second Quarter 2021 Results and Provides Business Update
|
04 Aug, 2021 |
|
INmune Bio, Inc. to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, August 4
|
28 Jul, 2021 |
|
INmune Bio, Inc. Announces Design of Upcoming Phase 2 Alzheimer’s Disease Clinical Trial and New Phase 1b AD Biomarker Data
|
26 Jul, 2021 |
|
INmune Bio, Inc. Announces Poster Presentation and Plenary Talk at the Alzheimer’s Association International Conference 2021
|
19 Jul, 2021 |
|
INMUNE BIO, INC. ANNOUNCES $40 MILLION REGISTERED DIRECT OFFERING
|
14 Jul, 2021 |
|
INmune Bio, Inc. Announces First Patient Treated with NK cell priming “pseudokine” INKmune in High-Risk Myelodysplastic Syndrome (MDS)
|
12 Jul, 2021 |
|
INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution
|
14 Jun, 2021 |
|
INmune Bio, Inc. Announces Lead Drug Candidate XPro1595 Receives Chemical Drug Name pegipanermin from USAN
|
02 Jun, 2021 |
|
INmune Bio, Inc. to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and hosted by M-Vest on May 26th, 2021
|
24 May, 2021 |
|
INmune Bio, Inc. Announces First Quarter 2021 Results and Provides Business Update
|
05 May, 2021 |
|
INmune Bio, Inc. to Report First Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, May 5
|
28 Apr, 2021 |
|
INmune Bio, Inc. Announces Participation in Fireside Chat at the B Riley Neurosciences Conference
|
26 Apr, 2021 |
|
INmune Bio, Inc. Announces Professor Mark Lowdell, PhD, CSO to Deliver Presentations at Two Upcoming Medical Meetings
|
22 Mar, 2021 |
|
INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021
|
08 Mar, 2021 |
|
INmune Bio, Inc. Announces Fourth Quarter and Full Year 2020 Results and Provides Business Update
|
04 Mar, 2021 |
|
INmune Bio, Inc. to Report Fourth Quarter and Full Year 2020 Financial Results and Provide a Corporate Update on Thursday, March 4
|
25 Feb, 2021 |
|
INmune Bio, Inc. Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration Biomarkers in Patients with Alzheimer’s Disease in Phase 1b Trial
|
21 Jan, 2021 |
|
INmune Bio, Inc. to Host Key Opinion Leader Webinar on Thursday, January 21 at 8 AM ET
|
13 Jan, 2021 |
